va-Q-tec AG

  • WKN: 663668
  • ISIN: DE0006636681
  • Land: Deutschland

Nachricht vom 20.08.2018 | 10:45

Supervisory Board of va-Q-tec AG extends Management Board mandate of founder and CEO Dr. Joachim Kuhn

DGAP-News: va-Q-tec AG / Key word(s): Change of Personnel

20.08.2018 / 10:45
The issuer is solely responsible for the content of this announcement.

Press release

Supervisory Board of va-Q-tec AG extends Management Board mandate of founder and CEO Dr. Joachim Kuhn

- Contract of founder and CEO Dr. Joachim Kuhn extended until 31 December 2023

- Dr. Kuhn has already held a Managing Director position since the company was founded in 2001

Würzburg, 20 August 2018. va-Q-tec AG (ISIN DE0006636681 / WKN 663668), a technologically leading provider of highly efficient products and solutions in the thermal insulation area, announces that CEO Dr. Joachim Kuhn and the Supervisory Board unanimously decided at a meeting to extend the Management Board mandate of Dr. Kuhn by a period of five years. The Supervisory Board and Dr. Kuhn are thereby sending an important signal of continuity. Dr. Kuhn, whose doctorate is in physics, founded va-Q-tec AG in 2001 in Würzburg, since when he has played a quite significant role in advancing the company along its growth track. He floated the company on the stock market in 2016 and is the largest individual shareholder in the company with a 15.27% interest.

Dr. Gerald Hommel, Supervisory Board Chairman, comments on the extension of the Management Board mandate: "With va-Q-tec, Dr. Kuhn has not only brought a sustainable technology with great future potential to market maturity, but has also been responsible to a quite significantly for va-Q-tec's success to date. For this reason, we are pleased that with his expertise he will continue to lead the company over the coming five years."


IR contact
va-Q-tec AG
Felix Rau
Telephone: +49 931 35942 - 2973

cometis AG
Claudius Krause
Telephone: +49 611 - 20 585 5-28

About va-Q-tec
va-Q-tec is a leading supplier of high-performance products and solutions in thermal insulation and cold chain logistics. The company develops, produces and markets highly efficient and consequently thin vacuum insulation panels (VIPs) as well as phase change materials (PCMs) for reliable and energy-efficient temperature controlling. In addition, va-Q-tec produces passive thermal packaging systems (containers and boxes) through optimally integrating VIPs and PCMs, which can maintain constant temperatures, depending on type, up to 200 hours without external energy input. To implement temperature-sensitive logistics chains, va-Q-tec - within a global partner network - operates a fleet of rental containers and boxes meeting demanding thermal protection standards. Along with healthcare & logistics as the main market, va-Q-tec addresses the following further markets: Appliance & Food, Technics & Industry, Building and Mobility. The high-growth company, which was founded in 2001, is based in Würzburg, Germany. Further information:

20.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this


UniDevice AG: Rekord-Ergebnis in 2018

Nach starkem Schlussspurt hat die UniDevice AG in 2018 Umsatz und Ergebnis deutlich gesteigert. Der B2B-Broker für hochpreisige Smartphones sollte auch künftig eine hohe Nachfrage verzeichnen und von der Ausnutzung unterschiedlicher Preisniveaus in den verschiedenen Ländern profitieren. Der Umsatz soll 2019 auf mindestens 380 Mio. € und in 2020 auf mindestens 410 Mio. € ansteigen, nachdem 2018 317 Mio. € erreicht wurden. Bei einem ermittelten Kursziel in Höhe von 2,35 € lautet das Rating KAUFEN.

News im Fokus

Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2018

21. Februar 2019, 11:51

Aktueller Webcast

Ströer SE & Co. KGaA

Vorläufige Geschäftszahlen 2018

26. Februar 2019

Aktuelle Research-Studie

Sanochemia Pharmazeutika AG

Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy

21. Februar 2019